T1	Participants 157 192	advanced colorectal cancer patients
T2	Participants 615 656	advanced colorectal cancer (ACC) patients
T3	Participants 655 694	s treated in the phase III CAIRO2 study
T4	Participants 615 694	advanced colorectal cancer (ACC) patients treated in the phase III CAIRO2 study
